Trade & Channel Strategies 2023: An Interview with Cheryl Allen of Curatio Scientia

In an interview with Pharma Commerce editor Nicholas Saraceno, Cheryl Allen, Founding Partner, Curatio Scientia, talks about her breakout session, Enable Holistic Hub and Provider Services at the 2023 Trade & Channel Strategies conference.

Pharma Commerce: Based on your panel discussion, what is the importance of patient and provider access and support solutions?

Allen: From an importance perspective, those two stakeholders, you have the patients here, and the prescribers and support community. Providing access and support solutions based on the attributes of the product is incredibly important. Patients can be confused, especially when newly diagnosed. In the prescriber community, there's so much noise out there. Finding solutions that can be easily accessible by these two groups is going to be extremely important in the success of branded products.

Pharma Commerce: Can you share trends that you are seeing in the space?

Allen: Excited to say that because of some of the challenges with the pandemic we came through, decentralized clinical trials. We also have new ways of engaging patients from a technology perspective. Those are being brought into the patient services space. So, I'm really excited to talk about access and support solutions.

Pharma Commerce: What are key decision points when considering patient and provider access and support solutions?

Allen: My distinct colleagues will be speaking about different models. We'll have Spencer talking about telemedicine and those types of support models. Paul will be talking about specialty products, where you have some direct to consumer type of engagement. I'll be focusing in on the exclusive model. There are instances where a patient population is small enough and usually this is in rare disease, where the manufacturer has the opportunity to select an exclusive provider. This exclusive provider supports all of distribution, access, and ongoing patient services. Some key decision points there. Number one, will the prescriber community accept that exclusive model? Is this something new to them? Do you have to educate and if so, what does that look like? The second area would be the payers. What are the payers thinking about this? This is a known model for them. Third and probably as important is internal stakeholder perspective. After the decision is made to go exclusive, how do those internal stakeholders feel about that? Are we all feeling good? Once that product launches, what's the messaging? Message to market around that. What are the success factors for that?